SCHEMBL2148390

SCHEMBL2148390

c1ccc(-n2ccc(-c3ccncc3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTT P42858 1/20 0.46
DYRK1A Q13627 1/20 0.46
NOTUM Q6P988 1/20 0.45
FYN P06241 2/20 0.43
PTGS2 P35354 1/20 0.41
MAPK10 P53779 1/20 0.41
CYP2C9 P11712 1/20 0.41
SRC P12931 2/20 0.40
BRAF P15056 2/20 0.40
KDR P35968 2/20 0.40
CHEK1 O14757 1/20 0.40
GSK3B P49841 1/20 0.40
AR P10275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15072164 0.93 KMT2A (0.50) ALDH1A1KMT2ASMN1; SMN2HPGDKDM4E
SCHEMBL218118 0.88 KMT2A (0.57) ALDH1A1KMT2ASMN1; SMN2HPGDKDM4E
Ammonia Solution, Strong SCHEMBL10418488 0.86 KMT2A (0.55) ALDH1A1KMT2ASMN1; SMN2HPGDKDM4E
SCHEMBL7048807 0.82 SCN4A (0.51) ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL15941989 0.82 FLT3 (0.59) ALDH1A1SMN1; SMN2KDM4EDYRK1ANOTUM
Formamide SCHEMBL29227819 0.82 HTT (0.48) ALDH1A1KMT2ASMN1; SMN2HPGDKDM4E
SCHEMBL6677484 0.81 ALDH1A1 (0.50) ALDH1A1KMT2AKDM4EL3MBTL1HTT
SCHEMBL13679138 0.80 HTT (0.65) ALDH1A1KMT2ASMN1; SMN2HPGDKDM4E
SCHEMBL27260683 0.80 POLB (0.48) ALDH1A1KMT2ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL554497 0.80 KMT2A (0.55) KMT2ASMN1; SMN2KDM4EHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040983-A1 RAF KINASE INHIBITORS RUGA CORPORATION 2013-02-14 US disclosed
WO-2011085269-A1 RAF KINASE INHIBITORS SELEXAGEN THERAPEUTICS, INC. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040983-A1 RAF KINASE INHIBITORS BRAF, RAF1, ARAF ALDH1A1 2793/4885KMT2A 1823/4885SMN1; SMN2 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.